phase readout
saveNCT07686367: Testing the Anti-Cancer Drug, Brenetafusp (IMCF106C), in Rare Cancers
NOT_YET_RECRUITINGupdated 2h ago
community read0 votes
Sponsor: National Cancer Institute (NCI). Phase: PHASE2. Conditions: Metastatic Myxoid Liposarcoma, Metastatic Synovial Sarcoma, Unresectable Myxoid Liposarcoma, Unresectable Synovial Sarcoma
view source ↗
comments(0)
5-min edit window · permanent after that